The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates fall to just 3%. These economics have created a bottleneck that leaves patients waiting years for new treatments that rarely arrive.
Antisense oligonucleotides (ASOs), short synthetic strands of DNA or RNA that silence disease-causing genes, are beginning to rewrite those odds. With six new FDA approvals since 2023 and more than 50 candidates in active trials, ASOs are experiencing a long-anticipated breakout. Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides are shifting the odds through rational design.
Oncotelic Therapeutics Inc. (OTCQB: OTLC) aims to be at the forefront with OT-101 (Trabedersen), the only TGF-β2-specific antisense therapy in Phase 3 trials, targeting pancreatic cancer and other resistant malignancies. The company’s efforts highlight the potential of ASOs to address previously undruggable targets.
The accelerating regulatory momentum—six new antisense drugs gained FDA approval in 2023–2024, bringing total approvals above 20—underscores a paradigm shift. As rational design improves target specificity and reduces off-target effects, ASOs may offer faster development timelines and higher success rates. For investors and patients alike, the implications are significant: a new class of medicines that could reshape treatment landscapes for genetic disorders, cancers, and rare diseases.
For more information on Oncotelic Therapeutics, visit the company’s newsroom at ibn.fm/OTLC.
